Stem cells in the treatment of diabetes mellitus — Focus on mesenchymal stem cells

Päth, G; Perakakis, Nikolaos; Mantzoros, Christos S.; Seufert, Jochen

doi:10.1016/j.metabol.2018.10.005

Cited by 108 publications

(65 citation statements)

References 200 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Current strategies for generating IPCs are mainly based on approaches that mimic normal pancreas development. The obtained IPCs are supposed to express specific biological markers of normal β cells that identify a terminal differentiation status, such as MAFA (a basic leucine zipper transcription factor expressed in mature β cells and absent in pancreatic progenitors and other cell types), NEUROD1 (downstream factor of NGN3 expressed in most pancreatic endocrine cells, including β cells), and PDX1/NKX 6.1 (restricted coexpression in β cells), as well as key functional features of adult β cells, including glucose-stimulated insulin secretion (GSIS) and C-peptide secretion [9][10][11][12][13][14]. In addition, after implantation into DM patients or immunodeficient diabetic animals, these in vitro-generated IPCs or islet organoids should respond to changing blood glucose and produce sufficient insulin and finally reverse hyperglycemia.…”

Section: Introductionmentioning

confidence: 99%

Current progress in stem cell therapy for type 1 diabetes mellitus

2020

View full text Add to dashboard Cite

Type 1 diabetes mellitus (T1DM) is the most common chronic autoimmune disease in young patients and is characterized by the loss of pancreatic β cells; as a result, the body becomes insulin deficient and hyperglycemic. Administration or injection of exogenous insulin cannot mimic the endogenous insulin secreted by a healthy pancreas. Pancreas and islet transplantation have emerged as promising treatments for reconstructing the normal regulation of blood glucose in T1DM patients. However, a critical shortage of pancreases and islets derived from human organ donors, complications associated with transplantations, high cost, and limited procedural availability remain bottlenecks in the widespread application of these strategies. Attempts have been directed to accommodate the increasing population of patients with T1DM. Stem cell therapy holds great potential for curing patients with T1DM. With the advent of research on stem cell therapy for various diseases, breakthroughs in stem cell-based therapy for T1DM have been reported. However, many unsolved issues need to be addressed before stem cell therapy will be clinically feasible for diabetic patients. In this review, we discuss the current research advances in strategies to obtain insulin-producing cells (IPCs) from different precursor cells and in stem cell-based therapies for diabetes.

show abstract

Section: Introductionmentioning

confidence: 99%

Current progress in stem cell therapy for type 1 diabetes mellitus

2020

View full text Add to dashboard Cite

show abstract

“…However, it's important to highlight here that growing body of evidence support the notion that MSCs mostly mediate their therapeutic effects via their secretory/paracrine and immunomodulatory functions rather than their transdifferentiation potential in vivo (Päth et al, 2019).…”

Section: Differentiation and Cell Replacement Potential Of Wj-mscsmentioning

confidence: 88%

“…But still on the other hand, several elegant studies and review articles attempt to investigate the differentiation potential of MSCs into various lineages other than mesoderm (Urrutia et al, 2019). Insulin producing cells is definitely one of these lineages (Enderami et al, 2018;Päth et al, 2019;Pavathuparambil Abdul Manaph et al, 2019). Accordingly, we recommend that interested scientists should also consider developing novel strategies and enhancing induction protocols to generate IPCs from these WJ-MSCs.…”

Section: Future Perspectivesmentioning

confidence: 99%

Therapeutic Potential of Wharton’s Jelly Mesenchymal Stem Cells for Diabetes: Achievements and Challenges

Kamal

Kassem

2020

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Diabetes mellitus (DM) is an alarming metabolic disease in which insulin secreting β-cells are damaged to various extent. Unfortunately, although currently available treatments help to manage the disease, however, patients usually develop complications, as well as decreased life quality and increased mortality. Thus, efficient therapeutic interventions to treat diabetes are urgently warranted. During the past years, mesenchymal stem cells (MSCs) have made their mark as a potential weapon in various regenerative medicine applications. The main fascination about MSCs lies in their potential to exert reparative effects on an amazingly wide spectrum of tissue injury. This is further reinforced by their ease of isolation and large ex vivo expansion capacity, as well as demonstrated multipotency and immunomodulatory activities. Among all the sources of MSCs, those isolated from umbilical cord-Wharton's jelly (WJ-MSCs), have been proved to provide a great source of MSCs. WJ-MSCs do not impose any ethical concerns as those which exist regarding ESCs, and represent a readily available non-invasive source, and hence suggested to become the new gold standard for MSC-based therapies. In the current review, we shall overview achievements, as well as challenges/hurdles which are standing in the way to utilize WJ-MSCs as a novel efficient therapeutic modality for DM.

show abstract

“…Human embryonic stem cell (hESC)- [6] and induced pluripotent stem cell (iPSC)derived islet-like cells [7] have primarily been used to form islet-like clusters, but this is associated with a relatively high risk of neoplasia [8,9] and other ethical issues [10]. Against this background, induced β cells derived from BMSCs are a promising option given that they are easy to obtain and immunoregulation [11,12], and they can differentiate into osteoblasts, chondrocytes, and adipocytes [13,14] in vitro. There are many ways to obtain insulin-producing cells using BMSCs.…”

Section: Introductionmentioning

confidence: 99%

Transcriptome Analysis of the Transdifferentiation of canine BMSCs into Insulin Producing Cells

WANG

Dai

Zou

et al. 2020

Preprint

View full text Add to dashboard Cite

Background Bone marrow mesenchymal stem cells are a potential resource for the clinical therapy of certain diseases. Canine, as a companion animal, living in the same space with human, is an ideal new model for human diseases research. Because of the high prevalence of diabetes, alternative transplantation islets resource (i.e. insulin producing cells) for diabetes treatment will be in urgent need, which makes our research on the transdifferentiation of Bone marrow mesenchymal stem cells into insulin producing cells become more important.Result In this study, we completed the transdifferentiation process and achieved the transcriptome profiling of five samples with two biological duplicates, namely, “BMSCs”, “islets”, “stage1”, “stage2” and “stage3”, and the latter three samples were achieved on the second, fifth and eighth day of induction. A total of 11,530 differentially expressed transcripts were revealed in the profiling data. The enrichment analysis of differentially expressed genes revealed several signaling pathways that are essential for regulating proliferation and transdifferentiation, including focal adhesion, ECM–receptor interaction, tight junction, protein digestion and absorption, and the Rap1 signaling pathway. Meanwhile, the obtained protein–protein interaction network and functional identification indicating involvement of three genes, SSTR2, RPS6KA6, and VIP could act as a foundation for further research.Conclusion In conclusion, to the best of our knowledge, this is the first survey of the transdifferentiation of canine BMSCs into insulin-producing cells according with the timeline using next-generation sequencing technology. The three key genes we pick out may regulate decisive genes during the development of transdifferentiation.

show abstract

Stem cells in the treatment of diabetes mellitus — Focus on mesenchymal stem cells

Cited by 108 publications

References 200 publications

Current progress in stem cell therapy for type 1 diabetes mellitus

Current progress in stem cell therapy for type 1 diabetes mellitus

Therapeutic Potential of Wharton’s Jelly Mesenchymal Stem Cells for Diabetes: Achievements and Challenges

Transcriptome Analysis of the Transdifferentiation of canine BMSCs into Insulin Producing Cells

Contact Info

Product

Resources

About